Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FPR1 | P21462 | 4/20 | 0.56 |
| ▸ | FPR2 | P25090 | 4/20 | 0.56 |
| ▸ | ACE | P12821 | 6/20 | 0.55 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.53 |
| ▸ | NPY1R | P25929 | 1/20 | 0.52 |
| ▸ | NPY2R | P49146 | 1/20 | 0.52 |
| ▸ | NPY4R | P50391 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27066357 | 1.00 | FPR1 (0.56) | FPR1FPR2ACEFOLH1NPY1R | |
| SCHEMBL27066398 | 1.00 | FPR1 (0.56) | FPR1FPR2ACEFOLH1NPY1R | |
| SCHEMBL27066397 | 1.00 | FPR1 (0.56) | FPR1FPR2ACEFOLH1NPY1R | |
| SCHEMBL27066369 | 1.00 | FPR1 (0.56) | FPR1FPR2ACEFOLH1NPY1R | |
| SCHEMBL27066371 | 1.00 | FPR1 (0.56) | FPR1FPR2ACEFOLH1NPY1R | |
| SCHEMBL27066379 | 0.97 | FOLH1 (0.56) | FPR1FPR2ACEFOLH1NPY1R | |
| SCHEMBL27066401 | 0.97 | FOLH1 (0.56) | FPR1FPR2ACEFOLH1NPY1R | |
| SCHEMBL27066381 | 0.97 | FOLH1 (0.56) | FPR1FPR2ACEFOLH1NPY1R | |
| SCHEMBL1695336 | 0.96 | FOLH1 (0.57) | FPR1FPR2ACEFOLH1NPY1R | |
| SCHEMBL1695337 | 0.96 | FOLH1 (0.57) | FPR1FPR2ACEFOLH1NPY1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240024409-A1 | N-f-MLF DERIVATIVES THAT INHIBIT FORMYL PEPTIDE RECEPTORS FOR THE TREATMENT OF DISEASE | UNIVERSITY OF SOUTH ALABAMA (US) | 2024-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240024409-A1 | N-f-MLF DERIVATIVES THAT INHIBIT FORMYL PEPTIDE RECEPTORS FOR THE TREATMENT OF DISEASE | FPR1, FPR2, FPR3 | FPR1 1/4885FPR2 2/4885ACE 2554/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.